Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Oligodendroglioma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 25Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14sargramostim 12Radiotherapy, Intensity-Modulated 12Radiotherapy, Conformal 12Sirolimus 10Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8pembrolizumab 8Thalidomide 8Sorafenib 8Radiosurgery 8Gefitinib 8motexafin gadolinium 7aldesleukin 7Procarbazine 7Gene Expression Profiling 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × tandutinib × Sarcoma × Clear all
NCT00379080 2017-04-07

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
60 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡